Evidence map›Paper›PMID 28246583›Full record

ReviewWorld journal of clinical oncology2017

Three-dimensional bio-printing: A new frontier in oncology research.

Nitin Charbe, Paul A McCarron, Murtaza M Tambuwala

Abstract readReview
In one paragraph

Review in World journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Constructing anTranslational cancer research · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Three-DimensionalInternational journal of biological sciences · 2024
    Review
  7. Review
  8. Review
  9. A hitchhiker's guide to cancer models.Trends in biotechnology · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nitin CharbeNitin Charbe, Unit of Clinical Pharmacology, L. Sacco University Hospital, University of Milan, 20157 Milan, Italy.
Paul A McCarronNitin Charbe, Unit of Clinical Pharmacology, L. Sacco University Hospital, University of Milan, 20157 Milan, Italy.
Murtaza M TambuwalaNitin Charbe, Unit of Clinical Pharmacology, L. Sacco University Hospital, University of Milan, 20157 Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current research in oncology deploys methods that rely principally on two-dimensional (2D) mono-cell cultures and animal models. Although these methodologies have led to significant advancement in the development of novel experimental therapeutic agents with promising anticancer activity in the laboratory, clinicians still struggle to manage cancer in the clinical setting. The disappointing translational success is attributable mainly to poor representation and recreation of the cancer microenvironment present in human neoplasia. Three-dimensional (3D) bio-printed models could help to simulate this micro-environment, with recent bio-printing of live human cells demonstrating that effective

Indexed as

BiomaterialsCancerIn vitroIn vivoThree-dimensional bio-printing

Identifiers

PMID28246583
PMCPMC5309712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.